Extracellular regulation of VEGF: Isoforms, proteolysis, and vascular patterning

Cytokine and Growth Factor Reviews

Volumn 25, Issue 1, 2014, Pages 1-19

  Vempati, Prakash ^a   Popel, Aleksander S ^a   Mac Gabhann, Feilim ^a  

^a Johns Hopkins University   (United States)

Author keywords

Angiogenesis; Computational model; Extracellular matrix; Gradient; Mathematical model; Microenvironment; Protease; Receptor; Systems biology

Indexed keywords

ADAMTS1 PROTEIN; AFLIBERCEPT; BEVACIZUMAB; CONNECTIVE TISSUE GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 10; GAG PROTEIN; GELATINASE B; HEPARIN; HYPOXIA INDUCIBLE FACTOR 2ALPHA; ISOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; NEUROPILIN 1; PERLECAN; PLASMIN; PROTEIN KINASE B; PROTEOHEPARAN SULFATE; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN 113; VASCULOTROPIN 120; VASCULOTROPIN 121; VASCULOTROPIN 145; VASCULOTROPIN 164; VASCULOTROPIN 165; VASCULOTROPIN 188; VASCULOTROPIN 189; VASCULOTROPIN A; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ALTERNATIVE RNA SPLICING; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; BINDING AFFINITY; BINDING SITE; BLOOD VESSEL; BLOOD VESSEL FUNCTION; BLOOD VESSEL PERMEABILITY; BRANCHING MORPHOGENESIS; CARCINOGENESIS; CELL ACTIVATION; CELL FUNCTION; CELL INTERACTION; CELL SURFACE; CELLULAR DISTRIBUTION; CELLULAR SECRETION; DIFFUSION; DRUG ACTIVITY; DRUG PENETRATION; DRUG PROTEIN BINDING; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME RELEASE; EXON; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX SEQUESTRATION; GENE; HUMAN; IMMUNOCOMPETENT CELL; IN VIVO STUDY; INTERNALIZATION; INTUSSUSCEPTION; ISCHEMIC CARDIOMYOPATHY; LUNG ALVEOLUS EPITHELIUM; MATHEMATICAL MODEL; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PHENOTYPE; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN STABILITY; PROTEIN STRUCTURE; PROTEIN TRANSPORT; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; SPLITTING ANGIOGENESIS; SPROUTING ANGIOGENESIS; TISSUE DISTRIBUTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; VEGFA GENE;

ANGIOGENESIS; COMPUTATIONAL MODEL; EXTRACELLULAR MATRIX; GRADIENT; MATHEMATICAL MODEL; MICROENVIRONMENT; PROTEASE; RECEPTOR; SYSTEMS BIOLOGY;

ALTERNATIVE SPLICING; ANIMALS; EXTRACELLULAR MATRIX; FIBRINOLYSIN; GENE EXPRESSION REGULATION; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; MATRIX METALLOPROTEINASES; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; NEUROPILIN-1; PROTEIN ISOFORMS; PROTEOLYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84895806240     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2013.11.002     Document Type: Review

References (223)

1. Koch S., Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb Perspect Med 2012, 2:a006502.
2. Mac Gabhann F., Popel A.S. Systems biology of vascular endothelial growth factors. Microcirculation 2008, 15:715-738.
3. Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473:298-307.
4. Egginton S. In vivo shear stress response. Biochem Soc Trans 2011, 39:1633-1638.
5. Chung A.S., Ferrara N. Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol 2011, 27:563-584.
6. Liu G., Qutub A.A., Vempati P., Mac Gabhann F., Popel A.S. Module-based multiscale simulation of angiogenesis in skeletal muscle. Theor Biol Med Model 2011, 8:6.
7. Gustafsson T. Vascular remodelling in human skeletal muscle. Biochem Soc Trans 2011, 39:1628-1632.
8. Carmeliet P., Jain R.K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011, 10:417-427.
9. Claesson-Welsh L., Welsh M. VEGFA and tumour angiogenesis. J Intern Med 2013, 273:114-127.
10. Kinnunen K., Yla-Herttuala S. Vascular endothelial growth factors in retinal and choroidal neovascular diseases. Ann Med 2012, 44:1-17.
11. Wu F.T., Stefanini M.O., Mac Gabhann F., Kontos C.D., Annex B.H., Popel A.S. A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. J Cell Mol Med 2010, 14:528-552.
12. Ambati B.K., Nozaki M., Singh N., Takeda A., Jani P.D., Suthar T., et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature 2006, 443:993-997.
13. Lee S., Jilani S.M., Nikolova G.V., Carpizo D., Iruela-Arispe M.L. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 2005, 169:681-691.
14. Gerhardt H., Golding M., Fruttiger M., Ruhrberg C., Lundkvist A., Abramsson A., Jeltsch M., Mitchell C., Alitalo K., Shima D., Betsholtz C. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003, 161:1163-1177.
15. Ruhrberg C., Gerhardt H., Golding M., Watson R., Ioannidou S., Fujisawa H., Betsholtz C., Shima D.T. Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev 2002, 16:2684-2698.
16. Grunstein J., Masbad J.J., Hickey R., Giordano F., Johnson R.S. Isoforms of vascular endothelial growth factor act in a coordinate fashion To recruit and expand tumor vasculature. Mol Cell Biol 2000, 20:7282-7291.
17. Park J.E., Keller G.A., Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993, 4:1317-1326.
18. Ruiz de Almodovar C., Coulon C., Salin P.A., Knevels E., Chounlamountri N., Poesen K., Hermans K., Lambrechts D., Van Geyte K., Dhondt J., Dresselaers T., Renaud J., Aragones J., Zacchigna S., Geudens I., Gall D., Stroobants S., Mutin M., Dassonville K., Storkebaum E., Jordan B.F., Eriksson U., Moons L., D'Hooge R., Haigh J.J., Belin M.F., Schiffmann S., Van Hecke P., Gallez B., Vinckier S., Chedotal A., Honnorat J., Thomasset N., Carmeliet P., Meissirel C. Matrix-binding vascular endothelial growth factor (VEGF) isoforms guide granule cell migration in the cerebellum via VEGF receptor Flk1. J Neurosci 2010, 30:15052-15066.
19. Vempati P., Popel A.S., Mac Gabhann F. Formation of VEGF isoform-specific spatial distributions governing angiogenesis: computational analysis. BMC Syst Biol 2011, 5:59.
20. Chappell J.C., Taylor S.M., Ferrara N., Bautch V.L. Local guidance of emerging vessel sprouts requires soluble Flt-1. Dev Cell 2009, 17:377-386.
21. Hashambhoy Y.L., Chappell J.C., Peirce S.M., Bautch V.L., Mac Gabhann F. Computational modeling of interacting VEGF and soluble VEGF receptor concentration gradients. Front Physiol 2011, 2:62.
22. Kappas N.C., Zeng G., Chappell J.C., Kearney J.B., Hazarika S., Kallianos K.G., Patterson C., Annex B.H., Bautch V.L. The VEGF receptor Flt-1 spatially modulates Flk-1 signaling and blood vessel branching. J Cell Biol 2008, 181:847-858.
23. Ng Y.S. The biology of vascular endothelial cell growth factor isoforms. VEGF in development 2008, Bioscience. http://link.springer.com/book/10.1007/978-0-387-78632-2, C. Ruhrberg (Ed.).
24. Carmeliet P., Ng Y.S., Nuyens D., Theilmeier G., Brusselmans K., Cornelissen I., Ehler E., Kakkar V.V., Stalmans I., Mattot V., Perriard J.C., Dewerchin M., Flameng W., Nagy A., Lupu F., Moons L., Collen D., D'Amore P.A., Shima D.T. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med 1999, 5:495-502.
25. Ng Y.S., Rohan R., Sunday M.E., Demello D.E., D'Amore P.A. Differential expression of VEGF isoforms in mouse during development and in the adult. Dev Dyn 2001, 220:112-121.
26. Yuan A., Lin C.Y., Chou C.H., Shih C.M., Chen C.Y., Cheng H.W., Chen Y.F., Chen J.J., Chen J.H., Yang P.C., Chang C. Functional and structural characteristics of tumor angiogenesis in lung cancers overexpressing different VEGF isoforms assessed by DCE- and SSCE-MRI. PLoS ONE 2011, 6:e16062.
27. Kawamura H., Li X., Goishi K., van Meeteren L.A., Jakobsson L., Cebe-Suarez S., Shimizu A., Edholm D., Ballmer-Hofer K., Kjellen L., Klagsbrun M., Claesson-Welsh L. Neuropilin-1 in regulation of VEGF-induced activation of p38MAPK and endothelial cell organization. Blood Nov 1, 2008, 112(9):3638-3649. see PMID: 18664627.
28. Chen T.T., Luque A., Lee S., Anderson S.M., Segura T., Iruela-Arispe M.L. Anchorage of VEGF to the extracellular matrix conveys differential signaling responses to endothelial cells. J Cell Biol 2010, 188:595-609.
29. Gianni-Barrera R., Trani M., Fontanellaz C., Heberer M., Djonov V., Hlushchuk R., Banfi A. VEGF over-expression in skeletal muscle induces angiogenesis by intussusception rather than sprouting. Angiogenesis 2013, 16:123-136.
30. Harper S.J., Bates D.O. VEGF-A splicing: the key to anti-angiogenic therapeutics?. Nat Rev Cancer 2008, 8:880-887.
31. Grunewald F.S., Prota A.E., Giese A., Ballmer-Hofer K. Structure-function analysis of VEGF receptor activation and the role of coreceptors in angiogenic signaling. Biochim Biophys Acta 2010, 1804:567-580.
32. Eichmann A., Simons M. VEGF signaling inside vascular endothelial cells and beyond. Curr Opin Cell Biol 2012, 24:188-193.
33. Yu L., Wu X., Cheng Z., Lee C.V., LeCouter J., Campa C., Fuh G., Lowman H., Ferrara N. Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci 2008, 49:522-527.
34. Catena R., Larzabal L., Larrayoz M., Molina E., Hermida J., Agorreta J., Montes R., Pio R., Montuenga L.M., Calvo A. VEGF(1)(2)(1)b and VEGF(1)(6)(5)b are weakly angiogenic isoforms of VEGF-A. Mol Cancer 2010, 9:320.
35. Dokun A.O., Annex B.H. The VEGF165b "ICE-o-form" puts a chill on the VEGF story. Circ Res 2011, 109:246-247.
36. Harris S., Craze M., Newton J., Fisher M., Shima D.T., Tozer G.M., Kanthou C. Do anti-angiogenic VEGF (VEGFxxxb) isoforms exist? A cautionary tale. PLoS ONE 2012, 7:e35231.
37. Autiero M., Waltenberger J., Communi D., Kranz A., Moons L., Lambrechts D., Kroll J., Plaisance S., De Mol M., Bono F., Kliche S., Fellbrich G., Ballmer-Hofer K., Maglione D., Mayr-Beyrle U., Dewerchin M., Dombrowski S., Stanimirovic D., Van Hummelen P., Dehio C., Hicklin D.J., Persico G., Herbert J.M., Communi D., Shibuya M., Collen D., Conway E.M., Carmeliet P. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003, 9:936-943.
38. Mac Gabhann F., Popel A.S. Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells. Am J Physiol Heart Circ Physiol 2004, 286:H153-H164.
39. Mac Gabhann F., Popel A.S. Differential binding of VEGF isoforms to VEGF receptor 2 in the presence of neuropilin-1: a computational model. Am J Physiol Heart Circ Physiol 2005, 288:H2851-H2860.
40. Soker S., Takashima S., Miao H.Q., Neufeld G., Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998, 92:735-745.
41. Lanahan A., Zhang X., Fantin A., Zhuang Z., Rivera-Molina F., Speichinger K., Prahst C., Zhang J., Wang Y., Davis G., Toomre D., Ruhrberg C., Simons M. The neuropilin 1 cytoplasmic domain is required for VEGF-A-dependent arteriogenesis. Dev Cell 2013, 25:156-168.
42. Fantin A., Vieira J.M., Plein A., Denti L., Fruttiger M., Pollard J.W., Ruhrberg C. NRP1 acts cell autonomously in endothelium to promote tip cell function during sprouting angiogenesis. Blood 2013, 121:2352-2362.
43. Cebe Suarez S., Pieren M., Cariolato L., Arn S., Hoffmann U., Bogucki A., Manlius C., Wood J., Ballmer-Hofer K. A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. Cell Mol Life Sci 2006, 63:2067-2077.
44. Kawamura H., Li X., Harper S.J., Bates D.O., Claesson-Welsh L. Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity. Cancer Res 2008, 68:4683-4692.
45. Gengrinovitch S., Berman B., David G., Witte L., Neufeld G., Ron D. Glypican-1 is a VEGF165 binding proteoglycan that acts as an extracellular chaperone for VEGF165. J Biol Chem 1999, 274:10816-10822.
46. Fuster M.M., Wang L., Castagnola J., Sikora L., Reddi K., Lee P.H., Radek K.A., Schuksz M., Bishop J.R., Gallo R.L., Sriramarao P., Esko J.D. Genetic alteration of endothelial heparan sulfate selectively inhibits tumor angiogenesis. J Cell Biol 2007, 177:539-549.
47. Keyt B.A., Berleau L.T., Nguyen H.V., Chen H., Heinsohn H., Vandlen R., Ferrara N. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 1996, 271:7788-7795.
48. Krilleke D., DeErkenez A., Schubert W., Giri I., Robinson G.S., Ng Y.S., Shima D.T. Molecular mapping and functional characterization of the VEGF164 heparin-binding domain. J Biol Chem 2007, 282:28045-28056.
49. Fuh G., Garcia K.C., de Vos A.M. The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1. J Biol Chem 2000, 275:26690-26695.
50. Mac Gabhann F., Popel A.S. Interactions of VEGF isoforms with VEGFR-1, VEGFR-2, and neuropilin in vivo: a computational model of human skeletal muscle. Am J Physiol Heart Circ Physiol 2007, 292:H459-H474.
51. Cebe-Suarez S., Grunewald F.S., Jaussi R., Li X., Claesson-Welsh L., Spillmann D., Mercer A.A., Prota A.E., Ballmer-Hofer K. Orf virus VEGF-E NZ2 promotes paracellular NRP-1/VEGFR-2 coreceptor assembly via the peptide RPPR. FASEB J 2008, 22:3078-3086.
52. Pan Q., Chathery Y., Wu Y., Rathore N., Tong R.K., Peale F., Bagri A., Tessier-Lavigne M., Koch A.W., Watts R.J. Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting. J Biol Chem 2007, 282:24049-24056.
53. Gitay-Goren H., Soker S., Vlodavsky I., Neufeld G. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J Biol Chem 1992, 267:6093-6098.
54. Gluzman-Poltorak Z., Cohen T., Herzog Y., Neufeld G. Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165 [corrected]. J Biol Chem 2000, 275:18040-18045.
55. Favier B., Alam A., Barron P., Bonnin J., Laboudie P., Fons P., Mandron M., Herault J.P., Neufeld G., Savi P., Herbert J.M., Bono F. Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. Blood 2006, 108:1243-1250.
56. Delcombel R., Janssen L., Vassy R., Gammons M., Haddad O., Richard B., Letourneur D., Bates D., Hendricks C., Waltenberger J., Starzec A., Sounni N.E., Noel A., Deroanne C., Lambert C., Colige A. New prospects in the roles of the C-terminal domains of VEGF-A and their cooperation for ligand binding, cellular signaling and vessels formation. Angiogenesis Apr 2013, 16(2):353-371. PMID: 23254820.
57. Lee T.Y., Folkman J., Javaherian K. HSPG-binding peptide corresponding to the exon 6a-encoded domain of VEGF inhibits tumor growth by blocking angiogenesis in murine model. PLoS ONE 2010, 5:e9945.
58. Zhang H.T., Scott P.A., Morbidelli L., Peak S., Moore J., Turley H., Harris A.L., Ziche M., Bicknell R. The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo. Br J Cancer 2000, 83:63-68.
59. Jia H., Jezequel S., Lohr M., Shaikh S., Davis D., Soker S., Selwood D., Zachary I. Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF. Biochem Biophys Res Commun 2001, 283:164-173.
60. Plouet J., Moro F., Bertagnolli S., Coldeboeuf N., Mazarguil H., Clamens S., Bayard F. Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect. J Biol Chem 1997, 272:13390-13396.
61. Poltorak Z., Cohen T., Sivan R., Kandelis Y., Spira G., Vlodavsky I., Keshet E., Neufeld G. VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J Biol Chem 1997, 272:7151-7158.
62. Jingjing L., Srinivasan B., Roque R.S. Ectodomain shedding of VEGF183, a novel isoform of vascular endothelial growth factor, promotes its mitogenic activity in vitro. Angiogenesis 2001, 4:103-112.
63. Ancelin M., Buteau-Lozano H., Meduri G., Osborne-Pellegrin M., Sordello S., Plouet J., Perrot-Applanat M. A dynamic shift of VEGF isoforms with a transient and selective progesterone-induced expression of VEGF189 regulates angiogenesis and vascular permeability in human uterus. Proc Natl Acad Sci USA 2002, 99:6023-6028.
64. Ancelin M., Chollet-Martin S., Herve M.A., Legrand C., El Benna J., Perrot-Applanat M. Vascular endothelial growth factor VEGF189 induces human neutrophil chemotaxis in extravascular tissue via an autocrine amplification mechanism. Lab Invest 2004, 84:502-512.
65. Herve M.A., Buteau-Lozano H., Mourah S., Calvo F., Perrot-Applanat M. VEGF189 stimulates endothelial cells proliferation and migration in vitro and up-regulates the expression of Flk-1/KDR mRNA. Exp Cell Res 2005, 309:24-31.
66. Herve M.A., Buteau-Lozano H., Vassy R., Bieche I., Velasco G., Pla M., Perret G., Mourah S., Perrot-Applanat M. Overexpression of vascular endothelial growth factor 189 in breast cancer cells leads to delayed tumor uptake with dilated intratumoral vessels. Am J Pathol 2008, 172:167-178.
67. Vintonenko N., Pelaez-Garavito I., Buteau-Lozano H., Toullec A., Lidereau R., Perret G.Y., Bieche I., Perrot-Applanat M. Overexpression of VEGF189 in breast cancer cells induces apoptosis via NRP1 under stress conditions. Cell Adh Migr 2011, 5:332-343.
68. Houck K.A., Leung D.W., Rowland A.M., Winer J., Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 1992, 267:26031-26037.
69. Lundkvist A., Lee S., Iruela-Arispe L., Betsholtz C., Gerhardt H. Growth factor gradients in vascular patterning. Novartis Found Symp 2007, 283:194-201.
70. Hashimoto G., Inoki I., Fujii Y., Aoki T., Ikeda E., Okada Y. Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165. J Biol Chem 2002, 277:36288-36295.
71. Kurtagic E., Jedrychowski M.P., Nugent M.A. Neutrophil elastase cleaves VEGF to generate a VEGF fragment with altered activity. Am J Physiol Lung Cell Mol Physiol Mar 2009, 296(3):L534-L546. see PMID: 19136576.
72. Nakamura S., Morimoto N., Tsuruma K., Izuta H., Yasuda Y., Kato N., Ikeda T., Shimazawa M., Hara H. Tissue kallikrein inhibits retinal neovascularization via the cleavage of vascular endothelial growth factor-165. Arterioscler Thromb Vasc Biol 2011, 31:1041-1048.
73. Fukuhara J., Noda K., Murata M., Namba S., Kinoshita S., Dong Z., Ando R., Lennikov A., Kanda A., Ishida S. Tissue kallikrein attenuates choroidal neovascularization via cleavage of vascular endothelial growth factor. Invest Ophthalmol Vis Sci 2013, 54:274-279.
74. Vempati P., Mac Gabhann F., Popel A.S. Quantifying the proteolytic release of extracellular matrix-sequestered VEGF with a computational model. PLoS ONE 2010, 5:e11860.
75. Gutierrez J., Konecny G.E., Hong K., Burges A., Henry T.D., Lambiase P.D., Lee Wong W., Meng Y.G. A new ELISA for use in a 3-ELISA system to assess concentrations of VEGF splice variants and VEGF(110) in ovarian cancer tumors. Clin Chem 2008, 54:597-601.
76. Ito T.K., Ishii G., Chiba H., Ochiai A. The VEGF angiogenic switch of fibroblasts is regulated by MMP-7 from cancer cells. Oncogene 2007, 26:7194-7203.
77. Hawinkels L.J., Zuidwijk K., Verspaget H.W., de Jonge-Muller E.S., van Duijn W., Ferreira V., Fontijn R.D., David G., Hommes D.W., Lamers C.B., Sier C.F. VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis. Eur J Cancer 2008, 44:1904-1913.
78. Ito T.K., Ishii G., Saito S., Yano K., Hoshino A., Suzuki T., Ochiai A. Degradation of soluble VEGF receptor-1 by MMP-7 allows VEGF access to endothelial cells. Blood 2009, 113:2363-2369.
79. Mintz L, Savitzky K, Engel S. VEGF nucleic acid and amino acid sequences. US patent 6783954, 2004.
80. Tozer G.M., Akerman S., Cross N.A., Barber P.R., Bjorndahl M.A., Greco O., Harris S., Hill S.A., Honess D.J., Ireson C.R., Pettyjohn K.L., Prise V.E., Reyes-Aldasoro C.C., Ruhrberg C., Shima D.T., Kanthou C. Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors. Cancer Res 2008, 68:2301-2311.
81. Lee S., Chen T.T., Barber C.L., Jordan M.C., Murdock J., Desai S., Ferrara N., Nagy A., Roos K.P., Iruela-Arispe M.L. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007, 130:691-703.
82. Hoier B., Prats C., Qvortrup K., Pilegaard H., Bangsbo J., Hellsten Y. Subcellular localization and mechanism of secretion of vascular endothelial growth factor in human skeletal muscle. FASEB J Sep 2013, 27(9):3496-3504. see PMID: 23709615.
83. Liu L., Ratner B.D., Sage E.H., Jiang S. Endothelial cell migration on surface-density gradients of fibronectin, VEGF, or both proteins. Langmuir 2007, 23:11168-11173.
84. Stenzel D., Lundkvist A., Sauvaget D., Busse M., Graupera M., van der Flier A., Wijelath E.S., Murray J., Sobel M., Costell M., Takahashi S., Fassler R., Yamaguchi Y., Gutmann D.H., Hynes R.O., Gerhardt H. Integrin-dependent and -independent functions of astrocytic fibronectin in retinal angiogenesis. Development 2011, 138:4451-4463.
85. Anderson S.M., Shergill B., Barry Z.T., Manousiouthakis E., Chen T.T., Botvinick E., Platt M.O., Iruela-Arispe M.L., Segura T. VEGF internalization is not required for VEGFR-2 phosphorylation in bioengineered surfaces with covalently linked VEGF. Integr Biol (Camb) 2011, 3:887-896.
86. Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., Tanzawa K., Thorpe P., Itohara S., Werb Z., Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000, 2:737-744.
87. Wijelath E.S., Murray J., Rahman S., Patel Y., Ishida A., Strand K., Aziz S., Cardona C., Hammond W.P., Savidge G.F., Rafii S., Sobel M. Novel vascular endothelial growth factor binding domains of fibronectin enhance vascular endothelial growth factor biological activity. Circ Res 2002, 91:25-31.
88. Sahni A., Francis C.W. Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. Blood 2000, 96:3772-3778.
89. Wijelath E.S., Rahman S., Murray J., Patel Y., Savidge G., Sobel M. Fibronectin promotes VEGF-induced CD34 cell differentiation into endothelial cells. J Vasc Surg 2004, 39:655-660.
90. Sela S., Natanson-Yaron S., Zcharia E., Vlodavsky I., Yagel S., Keshet E. Local retention versus systemic release of soluble VEGF receptor-1 are mediated by heparin-binding and regulated by heparanase. Circ Res 2011, 108:1063-1070.
91. Luque A., Carpizo D.R., Iruela-Arispe M.L. ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165. J Biol Chem 2003, 278:23656-23665.
92. Mac Gabhann F., Ji J.W., Popel A.S. Multi-scale computational models of pro-angiogenic treatments in peripheral arterial disease. Ann Biomed Eng 2007, 35:982-994.
93. Suryawanshi A., Mulik S., Sharma S., Reddy P.B., Sehrawat S., Rouse B.T. Ocular neovascularization caused by herpes simplex virus type 1 infection results from breakdown of binding between vascular endothelial growth factor A and its soluble receptor. J Immunol 2011, 186:3653-3665.
94. Bhattacharjee G., Asplin I.R., Wu S.M., Gawdi G., Pizzo S.V. The conformation-dependent interaction of alpha 2-macroglobulin with vascular endothelial growth factor. A novel mechanism of alpha 2-macroglobulin/growth factor binding. J Biol Chem 2000, 275:26806-26811.
95. Gupta K., Gupta P., Wild R., Ramakrishnan S., Hebbel R.P. Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: effect on human microvascular endothelial cell proliferation and angiogenesis. Angiogenesis 1999, 3:147-158.
96. Kaur S., Martin-Manso G., Pendrak M.L., Garfield S.H., Isenberg J.S., Roberts D.D. Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47. J Biol Chem 2010, 285:38923-38932.
97. Sulpice E., Contreres J.O., Lacour J., Bryckaert M., Tobelem G. Platelet factor 4 disrupts the intracellular signalling cascade induced by vascular endothelial growth factor by both KDR dependent and independent mechanisms. Eur J Biochem 2004, 271:3310-3318.
98. Purushothaman A., Uyama T., Kobayashi F., Yamada S., Sugahara K., Rapraeger A.C., Sanderson R.D. Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood 2010, 115:2449-2457.
99. Flaumenhaft R., Moscatelli D., Rifkin D.B. Heparin and heparan sulfate increase the radius of diffusion and action of basic fibroblast growth factor. J Cell Biol 1990, 111:1651-1659.
100. Makarenkova H.P., Hoffman M.P., Beenken A., Eliseenkova A.V., Meech R., Tsau C., Patel V.N., Lang R.A., Mohammadi M. Differential interactions of FGFs with heparan sulfate control gradient formation and branching morphogenesis. Sci Signal 2009, 2:ra55.
101. Kleinheinz J., Jung S., Wermker K., Fischer C., Joos U. Release kinetics of VEGF165 from a collagen matrix and structural matrix changes in a circulation model. Head Face Med 2010, 6:17.
102. Ekker S.C., Bedell V.M. The ins and outs of VEGF signaling. Blood 2009, 113:2123-2124.
103. Ghajar C.M., George S.C., Putnam A.J. Matrix metalloproteinase control of capillary morphogenesis. Crit Rev Eukaryot Gene Expr 2008, 18:251-278.
104. Lauer G., Sollberg S., Cole M., Flamme I., Sturzebecher J., Mann K., Krieg T., Eming S.A. Expression and proteolysis of vascular endothelial growth factor is increased in chronic wounds. J Invest Dermatol 2000, 115:12-18.
105. Roth D., Piekarek M., Paulsson M., Christ H., Bloch W., Krieg T., Davidson J.M., Eming S.A. Plasmin modulates vascular endothelial growth factor-A-mediated angiogenesis during wound repair. Am J Pathol 2006, 168:670-684.
106. Ehrbar M., Djonov V.G., Schnell C., Tschanz S.A., Martiny-Baron G., Schenk U., Wood J., Burri P.H., Hubbell J.A., Zisch A.H. Cell-demanded liberation of VEGF121 from fibrin implants induces local and controlled blood vessel growth. Circ Res 2004, 94:1124-1132.
107. Bonnefoy A., Legrand C. Proteolysis of subendothelial adhesive glycoproteins (fibronectin, thrombospondin, and von Willebrand factor) by plasmin, leukocyte cathepsin G, and elastase. Thromb Res 2000, 98:323-332.
108. Mochizuki S., Tanaka R., Shimoda M., Onuma J., Fujii Y., Jinno H., Okada Y. Connective tissue growth factor is a substrate of ADAM28. Biochem Biophys Res Commun 2010, 402:651-657.
109. Joyce J.A., Freeman C., Meyer-Morse N., Parish C.R., Hanahan D. A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene 2005, 24:4037-4051.
110. Whitelock J.M., Murdoch A.D., Iozzo R.V., Underwood P.A. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem 1996, 271:10079-10086.
111. Rodriguez-Manzaneque J.C., Lane T.F., Ortega M.A., Hynes R.O., Lawler J., Iruela-Arispe M.L. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci USA 2001, 98:12485-12490.
112. Ardi V.C., Kupriyanova T.A., Deryugina E.I., Quigley J.P. Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc Natl Acad Sci USA 2007, 104:20262-20267.
113. Du R., Lu K.V., Petritsch C., Liu P., Ganss R., Passegue E., Song H., Vandenberg S., Johnson R.S., Werb Z., Bergers G. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008, 13:206-220.
114. Giraudo E., Inoue M., Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 2004, 114:623-633.
115. Nozawa H., Chiu C., Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA 2006, 103:12493-12498.
116. Greenaway J., Lawler J., Moorehead R., Bornstein P., Lamarre J., Petrik J. Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1). J Cell Physiol 2007, 210:807-818.
117. Mineur P., Colige A.C., Deroanne C.F., Dubail J., Kesteloot F., Habraken Y., Noel A., Voo S., Waltenberger J., Lapiere C.M., Nusgens B.V., Lambert C.A. Newly identified biologically active and proteolysis-resistant VEGF-A isoform VEGF111 is induced by genotoxic agents. J Cell Biol 2007, 179:1261-1273.
118. Lauer G., Sollberg S., Cole M., Krieg T., Eming S.A. Generation of a novel proteolysis resistant vascular endothelial growth factor165 variant by a site-directed mutation at the plasmin sensitive cleavage site. FEBS Lett 2002, 531:309-313.
119. Chen R.R., Silva E.A., Yuen W.W., Brock A.A., Fischbach C., Lin A.S., Guldberg R.E., Mooney D.J. Integrated approach to designing growth factor delivery systems. FASEB J 2007, 21:3896-3903.
120. Serini G., Ambrosi D., Giraudo E., Gamba A., Preziosi L., Bussolino F. Modeling the early stages of vascular network assembly. EMBO J 2003, 22:1771-1779.
121. Ferrara N. Binding to the extracellular matrix and proteolytic processing: two key mechanisms regulating vascular endothelial growth factor action. Mol Biol Cell 2010, 21:687-690.
122. Mitchell C.A., Rutland C.S., Walker M., Nasir M., Foss A.J., Stewart C., Gerhardt H., Konerding M.A., Risau W., Drexler H.C. Unique vascular phenotypes following over-expression of individual VEGFA isoforms from the developing lens. Angiogenesis 2006, 9:209-224.
123. Kut C., Mac Gabhann F., Popel A.S. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer 2007, 97:978-985.
124. Morbidelli L., Birkenhaeger R., Roeckl W., Granger H.J., Kaerst U., Weich H.A., Ziche M. Distinct capillary density and progression promoted by vascular endothelial growth factor-A homodimers and heterodimers. Angiogenesis 1997, 1:117-130.
125. Stalmans I., Ng Y.S., Rohan R., Fruttiger M., Bouche A., Yuce A., Fujisawa H., Hermans B., Shani M., Jansen S., Hicklin D., Anderson D.J., Gardiner T., Hammes H.P., Moons L., Dewerchin M., Collen D., Carmeliet P., D'Amore P.A. Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest 2002, 109:327-336.
126. Gerhardt H. VEGF and endothelial guidance in angiogenic sprouting. Organogenesis 2008, 4:241-246.
127. Eldar A., Rosin D., Shilo B.Z., Barkai N. Self-enhanced ligand degradation underlies robustness of morphogen gradients. Dev Cell 2003, 5:635-646.
128. Lander A.D. Morpheus unbound: reimagining the morphogen gradient. Cell 2007, 128:245-256.
129. Kicheva A., Pantazis P., Bollenbach T., Kalaidzidis Y., Bittig T., Julicher F., Gonzalez-Gaitan M. Kinetics of morphogen gradient formation. Science 2007, 315:521-525.
130. Zoeller J.J., Whitelock J.M., Iozzo R.V. Perlecan regulates developmental angiogenesis by modulating the VEGF-VEGFR2 axis. Matrix Biol 2009, 28:284-291.
131. Akeson A.L., Greenberg J.M., Cameron J.E., Thompson F.Y., Brooks S.K., Wiginton D., Whitsett J.A. Temporal and spatial regulation of VEGF-A controls vascular patterning in the embryonic lung. Dev Biol 2003, 264:443-455.
132. Jubb A.M., Strickland L.A., Liu S.D., Mak J., Schmidt M., Koeppen H. Neuropilin-1 expression in cancer and development. J Pathol 2012, 226:50-60.
133. Nakayama M., Nakayama A., van Lessen M., Yamamoto H., Hoffmann S., Drexler H.C., Itoh N., Hirose T., Breier G., Vestweber D., Cooper J.A., Ohno S., Kaibuchi K., Adams R.H. Spatial regulation of VEGF receptor endocytosis in angiogenesis. Nat Cell Biol 2013, 15:249-260.
134. Finley S.D., Engel-Stefanini M.O., Imoukhuede P.I., Popel A.S. Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies. BMC Syst Biol 2011, 5:193.
135. Rosenstein J.M., Krum J.M. New roles for VEGF in nervous tissue--beyond blood vessels. Exp Neurol 2004, 187:246-253.
136. Stollman T.H., Scheer M.G., Franssen G.M., Verrijp K.N., Oyen W.J., Ruers T.J., Leenders W.P., Boerman O.C. Tumor accumulation of radiolabeled bevacizumab due to targeting of cell- and matrix-associated VEGF-A isoforms. Cancer Biother Radiopharm 2009, 24:195-200.
137. Mira E., Lacalle R.A., Buesa J.M., de Buitrago G.G., Jimenez-Baranda S., Gomez-Mouton C., Martinez A.C., Manes S. Secreted MMP9 promotes angiogenesis more efficiently than constitutive active MMP9 bound to the tumor cell surface. J Cell Sci 2004, 117:1847-1857.
138. Christofori G., Naik P., Hanahan D. Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Mol Endocrinol 1995, 9:1760-1770.
139. Zetser A., Bashenko Y., Edovitsky E., Levy-Adam F., Vlodavsky I., Ilan N. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res 2006, 66:1455-1463.
140. Ebrahem Q., Chaurasia S.S., Vasanji A., Qi J.H., Klenotic P.A., Cutler A., Asosingh K., Erzurum S., Anand-Apte B. Cross-talk between vascular endothelial growth factor and matrix metalloproteinases in the induction of neovascularization in vivo. Am J Pathol 2010, 176:496-503.
141. Helm C.L., Fleury M.E., Zisch A.H., Boschetti F., Swartz M.A. Synergy between interstitial flow and VEGF directs capillary morphogenesis in vitro through a gradient amplification mechanism. Proc Natl Acad Sci USA 2005, 102:15779-15784.
142. Stefanini M.O., Wu F.T., Mac Gabhann F., Popel A.S. Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model. Cancer Res 2010, 70:9886-9894.
143. Wu F.T., Stefanini M.O., Mac Gabhann F., Kontos C.D., Annex B.H., Popel A.S. Computational kinetic model of VEGF trapping by soluble VEGF receptor-1: effects of transendothelial and lymphatic macromolecular transport. Physiol Genomics 2009, 38:29-41.
144. Finley S.D., Dhar M., Popel A.S. Compartment model predicts VEGF secretion and investigates the effects of VEGF trap in tumor-bearing mice. Front Oncol 2013, 3:196.
145. Finley S.D., Popel A.S. Effect of tumor microenvironment on tumor vegf during anti-VEGF treatment: systems biology predictions. J Natl Cancer Inst 2013, 105:802-811.
146. Rudge J.S., Holash J., Hylton D., Russell M., Jiang S., Leidich R., Papadopoulos N., Pyles E.A., Torri A., Wiegand S.J., Thurston G., Stahl N., Yancopoulos G.D. VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci USA 2007, 104:18363-18370.
147. Segerstrom L., Fuchs D., Backman U., Holmquist K., Christofferson R., Azarbayjani F. The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts. Pediatr Res 2006, 60:576-581.
148. Willett C.G., Boucher Y., Duda D.G., di Tomaso E., Munn L.L., Tong R.T., Kozin S.V., Petit L., Jain R.K., Chung D.C., Sahani D.V., Kalva S.P., Cohen K.S., Scadden D.T., Fischman A.J., Clark J.W., Ryan D.P., Zhu A.X., Blaszkowsky L.S., Shellito P.C., Mino-Kenudson M., Lauwers G.Y. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005, 23:8136-8139.
149. Gu C., Limberg B.J., Whitaker G.B., Perman B., Leahy D.J., Rosenbaum J.S., Ginty D.D., Kolodkin A.L. Characterization of neuropilin-1 structural features that confer binding to semaphorin 3A and vascular endothelial growth factor 165. J Biol Chem 2002, 277:18069-18076.
150. Blanco R., Gerhardt H. VEGF and Notch in tip and stalk cell selection. Cold Spring Harb Perspect Med 2013, 3:a006569.
151. Ziyad S., Iruela-Arispe M.L. Molecular mechanisms of tumor angiogenesis. Genes Cancer 2011, 2:1085-1096.
152. Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., Fahrig M., Vandenhoeck A., Harpal K., Eberhardt C., Declercq C., Pawling J., Moons L., Collen D., Risau W., Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996, 380:435-439.
153. Miquerol L., Langille B.L., Nagy A. Embryonic development is disrupted by modest increases in vascular endothelial growth factor gene expression. Development 2000, 127:3941-3946.
154. Berse B., Brown L.F., Van de Water L., Dvorak H.F., Senger D.R. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 1992, 3:211-220.
155. Saint-Geniez M., Maldonado A.E., D'Amore P.A. VEGF expression and receptor activation in the choroid during development and in the adult. Invest Ophthalmol Vis Sci 2006, 47:3135-3142.
156. Zhang Q.X., Magovern C.J., Mack C.A., Budenbender K.T., Ko W., Rosengart T.K. Vascular endothelial growth factor is the major angiogenic factor in omentum: mechanism of the omentum-mediated angiogenesis. J Surg Res 1997, 67:147-154.
157. Lazarus A., Keshet E. Vascular endothelial growth factor and vascular homeostasis. Proc Am Thorac Soc 2011, 8:508-511.
158. Maharaj A.S., D'Amore P.A. Roles for VEGF in the adult. Microvasc Res 2007, 74:100-113.
159. Marti H.H., Risau W. Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. Proc Natl Acad Sci USA 1998, 95:15809-15814.
160. Makanya A.N., Stauffer D., Ribatti D., Burri P.H., Djonov V. Microvascular growth, development, and remodeling in the embryonic avian kidney: the interplay between sprouting and intussusceptive angiogenic mechanisms. Microsc Res Tech 2005, 66:275-288.
161. Makanya A.N., Hlushchuk R., Djonov V.G. Intussusceptive angiogenesis and its role in vascular morphogenesis, patterning, and remodeling. Angiogenesis 2009, 12:113-123.
162. De Spiegelaere W., Casteleyn C., Van den Broeck W., Plendl J., Bahramsoltani M., Simoens P., Djonov V., Cornillie P. Intussusceptive angiogenesis: a biologically relevant form of angiogenesis. J Vasc Res 2012, 49:390-404.
163. Baum O., Suter F., Gerber B., Tschanz S.A., Buergy R., Blank F., Hlushchuk R., Djonov V. VEGF-A promotes intussusceptive angiogenesis in the developing chicken chorioallantoic membrane. Microcirculation 2010, 17:447-457.
164. Xu D., Fuster M.M., Lawrence R., Esko J.D. Heparan sulfate regulates VEGF165- and VEGF121-mediated vascular hyperpermeability. J Biol Chem 2011, 286:737-745.
165. Usui T., Ishida S., Yamashiro K., Kaji Y., Poulaki V., Moore J., Moore T., Amano S., Horikawa Y., Dartt D., Golding M., Shima D.T., Adamis A.P. VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Invest Ophthalmol Vis Sci 2004, 45:368-374.
166. Ng I.O., Poon R.T., Lee J.M., Fan S.T., Ng M., Tso W.K. Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. Am J Clin Pathol 2001, 116:838-845.
167. Mattot V., Moons L., Lupu F., Chernavvsky D., Gomez R.A., Collen D., Carmeliet P. Loss of the VEGF(164) and VEGF(188) isoforms impairs postnatal glomerular angiogenesis and renal arteriogenesis in mice. J Am Soc Nephrol 2002, 13:1548-1560.
168. Maes C., Carmeliet P., Moermans K., Stockmans I., Smets N., Collen D., Bouillon R., Carmeliet G. Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Mech Dev 2002, 111:61-73.
169. Kusters B., de Waal R.M., Wesseling P., Verrijp K., Maass C., Heerschap A., Barentsz J.O., Sweep F., Ruiter D.J., Leenders W.P. Differential effects of vascular endothelial growth factor A isoforms in a mouse brain metastasis model of human melanoma. Cancer Res 2003, 63:5408-5413.
170. Cheng S.Y., Nagane M., Huang H.S., Cavenee W.K. Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189. Proc Natl Acad Sci USA 1997, 94:12081-12087.
171. Fenton B.M., Paoni S.F., Liu W., Cheng S.Y., Hu B., Ding I. Overexpression of VEGF121, but not VEGF165 or FGF-1, improves oxygenation in MCF-7 breast tumours. Br J Cancer 2004, 90:430-435.
172. Springer M.L., Banfi A., Ye J., von Degenfeld G., Kraft P.E., Saini S.A., Kapasi N.K., Blau H.M. Localization of vascular response to VEGF is not dependent on heparin binding. FASEB J 2007, 21:2074-2085.
173. Geudens I., Gerhardt H. Coordinating cell behaviour during blood vessel formation. Development 2011, 138:4569-4583.
174. Logsdon E.A., Finley S.D., Popel A.S., Mac Gabhann F. A systems biology view of blood vessel growth and remodeling. J Cell Mol Med Nov 17 2013, PMID: 24237862. 10.1111/jcmm.12164.
175. Jakobsson L., Franco C.A., Bentley K., Collins R.T., Ponsioen B., Aspalter I.M., Rosewell I., Busse M., Thurston G., Medvinsky A., Schulte-Merker S., Gerhardt H. Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting. Nat Cell Biol 2010, 12:943-953.
176. Arima S., Nishiyama K., Ko T., Arima Y., Hakozaki Y., Sugihara K., Koseki H., Uchijima Y., Kurihara Y., Kurihara H. Angiogenic morphogenesis driven by dynamic and heterogeneous collective endothelial cell movement. Development 2011, 138:4763-4776.
177. Nakatsu M.N., Sainson R.C., Perez-del-Pulgar S., Aoto J.N., Aitkenhead M., Taylor K.L., Carpenter P.M., Hughes C.C. VEGF(121) and VEGF(165) regulate blood vessel diameter through vascular endothelial growth factor receptor 2 in an in vitro angiogenesis model. Lab Invest 2003, 83:1873-1885.
178. von Degenfeld G., Banfi A., Springer M.L., Wagner R.A., Jacobi J., Ozawa C.R., Merchant M.J., Cooke J.P., Blau H.M. Microenvironmental VEGF distribution is critical for stable and functional vessel growth in ischemia. FASEB J 2006, 20:2657-2659.
179. Gerhardt H., Ruhrberg C., Abramsson A., Fujisawa H., Shima D., Betsholtz C. Neuropilin-1 is required for endothelial tip cell guidance in the developing central nervous system. Dev Dyn 2004, 231:503-509.
180. Bentley K., Gerhardt H., Bates P.A. Agent-based simulation of notch-mediated tip cell selection in angiogenic sprout initialisation. J Theor Biol 2008, 250:25-36.
181. Song J.W., Munn L.L. Fluid forces control endothelial sprouting. Proc Natl Acad Sci USA 2011, 108:15342-15347.
182. Barkefors I., Le Jan S., Jakobsson L., Hejll E., Carlson G., Johansson H., Jarvius J., Park J.W., Li Jeon N., Kreuger J. Endothelial cell migration in stable gradients of vascular endothelial growth factor A and fibroblast growth factor 2: effects on chemotaxis and chemokinesis. J Biol Chem 2008, 283:13905-13912.
183. Bentley K., Jones M., Cruys B. Predicting the future: towards symbiotic computational and experimental angiogenesis research. Exp Cell Res 2013, 319:1240-1246.
184. Noguera-Troise I., Daly C., Papadopoulos N.J., Coetzee S., Boland P., Gale N.W., Lin H.C., Yancopoulos G.D., Thurston G. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006, 444:1032-1037.
185. Scehnet J.S., Jiang W., Kumar S.R., Krasnoperov V., Trindade A., Benedito R., Djokovic D., Borges C., Ley E.J., Duarte A., Gill P.S. Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood 2007, 109:4753-4760.
186. Benedito R., Hellstrom M. Notch as a hub for signaling in angiogenesis. Exp Cell Res 2013, 319:1281-1288.
187. Carlier A., Geris L., Bentley K., Carmeliet G., Carmeliet P., Van Oosterwyck H. MOSAIC: a multiscale model of osteogenesis and sprouting angiogenesis with lateral inhibition of endothelial cells. PLoS Comput Biol 2012, 8:e1002724.
188. Ehrbar M., Zeisberger S.M., Raeber G.P., Hubbell J.A., Schnell C., Zisch A.H. The role of actively released fibrin-conjugated VEGF for VEGF receptor 2 gene activation and the enhancement of angiogenesis. Biomaterials 2008, 29:1720-1729.
189. Jakobsson L., Kreuger J., Holmborn K., Lundin L., Eriksson I., Kjellen L., Claesson-Welsh L. Heparan sulfate in trans potentiates VEGFR-mediated angiogenesis. Dev Cell 2006, 10:625-634.
190. Fukumura D., Jain R.K. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res 2007, 74:72-84.
191. Nagy J.A., Chang S.H., Shih S.C., Dvorak A.M., Dvorak H.F. Heterogeneity of the tumor vasculature. Semin Thromb Hemost 2010, 36:321-331.
192. Nagy J.A., Chang S.H., Dvorak A.M., Dvorak H.F. Why are tumour blood vessels abnormal and why is it important to know?. Br J Cancer 2009, 100:865-869.
193. Ribatti D., Djonov V. Intussusceptive microvascular growth in tumors. Cancer Lett 2012, 316:126-131.
194. Gianni-Barrera R., Trani M., Reginato S., Banfi A. To sprout or to split?. VEGF, Notch and vascular morphogenesis. Biochem Soc Trans 2011, 39:1644-1648.
195. Egginton S. Invited review: activity-induced angiogenesis. Pflugers Arch 2009, 457:963-977.
196. Egginton S., Zhou A.L., Brown M.D., Hudlicka O. Unorthodox angiogenesis in skeletal muscle. Cardiovasc Res 2001, 49:634-646.
197. Ji J.W., Tsoukias N.M., Goldman D., Popel A.S. A computational model of oxygen transport in skeletal muscle for sprouting and splitting modes of angiogenesis. J Theor Biol 2006, 241:94-108.
198. Hlushchuk R., Makanya A.N., Djonov V. Escape mechanisms after antiangiogenic treatment, or why are the tumors growing again?. Int J Dev Biol 2011, 55:563-567.
199. Springer M.L., Chen A.S., Kraft P.E., Bednarski M., Blau H.M. VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Mol Cell 1998, 2:549-558.
200. Pettersson A., Nagy J.A., Brown L.F., Sundberg C., Morgan E., Jungles S., Carter R., Krieger J.E., Manseau E.J., Harvey V.S., Eckelhoefer I.A., Feng D., Dvorak A.M., Mulligan R.C., Dvorak H.F. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab Invest 2000, 80:99-115.
201. Rivron N.C., Vrij E.J., Rouwkema J., Le Gac S., van den Berg A., Truckenmuller R.K., van Blitterswijk C.A. Tissue deformation spatially modulates VEGF signaling and angiogenesis. Proc Natl Acad Sci USA 2012, 109:6886-6891.
202. Ozawa C.R., Banfi A., Glazer N.L., Thurston G., Springer M.L., Kraft P.E., McDonald D.M., Blau H.M. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J Clin Invest 2004, 113:516-527.
203. Sundberg C., Nagy J.A., Brown L.F., Feng D., Eckelhoefer I.A., Manseau E.J., Dvorak A.M., Dvorak H.F. Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery. Am J Pathol 2001, 158:1145-1160.
204. Dome B., Hendrix M.J., Paku S., Tovari J., Timar J. Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am J Pathol 2007, 170:1-15.
205. Pan Q., Chanthery Y., Liang W.C., Stawicki S., Mak J., Rathore N., Tong R.K., Kowalski J., Yee S.F., Pacheco G., Ross S., Cheng Z., Le Couter J., Plowman G., Peale F., Koch A.W., Wu Y., Bagri A., Tessier-Lavigne M., Watts R.J. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 2007, 11:53-67.
206. Akerman S., Fisher M., Daniel R.A., Lefley D., Reyes-Aldasoro C.C., Lunt S.J., Harris S., Bjorndahl M., Williams L.J., Evans H., Barber P.R., Prise V.E., Vojnovic B., Kanthou C., Tozer G.M. Influence of soluble or matrix-bound isoforms of vascular endothelial growth factor-A on tumor response to vascular-targeted strategies. Int J Cancer Dec 1, 2013, 133(11):2563-2576. see PMID: 23712501.
207. Franco M., Roswall P., Cortez E., Hanahan D., Pietras K. Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression. Blood 2011, 118:2906-2917.
208. Zisch A.H., Schenk U., Schense J.C., Sakiyama-Elbert S.E., Hubbell J.A. Covalently conjugated VEGF-fibrin matrices for endothelialization. J Control Release 2001, 72:101-113.
209. Goel S., Duda D.G., Xu L., Munn L.L., Boucher Y., Fukumura D., Jain R.K. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011, 91:1071-1121.
210. Straume O., Chappuis P.O., Salvesen H.B., Halvorsen O.J., Haukaas S.A., Goffin J.R., Begin L.R., Foulkes W.D., Akslen L.A. Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers. Cancer Res 2002, 62:6808-6811.
211. Tanaka F., Oyanagi H., Takenaka K., Ishikawa S., Yanagihara K., Miyahara R., Kawano Y., Li M., Otake Y., Wada H. Glomeruloid microvascular proliferation is superior to intratumoral microvessel density as a prognostic marker in non-small cell lung cancer. Cancer Res 2003, 63:6791-6794.
212. Sitohy B., Nagy J.A., Jaminet S.C., Dvorak H.F. Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy. Cancer Res 2011, 71:7021-7028.
213. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001, 7:987-989.
214. Akerman S., Reyes-Aldasoro C.C., Fisher M., Pettyjohn K.L., Bjorndahl M.A., Evans H., Tozer G.M. Microflow of fluorescently labelled red blood cells in tumours expressing single isoforms of VEGF and their response to vascular targeting agents. Med Eng Phys 2011, 33:805-809.
215. Indraccolo S., Favaro E., Amadori A. Dormant tumors awaken by a short-term angiogenic burst: the spike hypothesis. Cell Cycle 2006, 5:1751-1755.
216. Milde F., Bergdorf M., Koumoutsakos P. A hybrid model for three-dimensional simulations of sprouting angiogenesis. Biophys J 2008, 95:3146-3160.
217. Qutub A.A., Mac Gabhann F., Karagiannis E.D., Vempati P., Popel A.S. Multiscale models of angiogenesis. IEEE Eng Med Biol Mag 2009, 28:14-31.
218. Qutub A.A., Popel A.S. Elongation, proliferation & migration differentiate endothelial cell phenotypes and determine capillary sprouting. BMC Syst Biol 2009, 3:13.
219. Travasso R.D., Corvera Poire E., Castro M., Rodriguez-Manzaneque J.C., Hernandez-Machado A. Tumor angiogenesis and vascular patterning: a mathematical model. PLoS ONE 2011, 6:e19989.
220. Amyot F., Small A., Boukari H., Camphausen K., Gandjbakhche A. Topology of the heterogeneous nature of the extracellular matrix on stochastic modeling of tumor-induced angiogenesis. Microvasc Res 2009, 77:87-95.
221. Bauer A.L., Jackson T.L., Jiang Y. Topography of extracellular matrix mediates vascular morphogenesis and migration speeds in angiogenesis. PLoS Comput Biol 2009, 5:e1000445.
222. Belotti D., Paganoni P., Manenti L., Garofalo A., Marchini S., Taraboletti G., Giavazzi R. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res 2003, 63:5224-5229.
223. Gaspar N.J., Jue R.A., Hu J., Puchacz E., deForest N.L., Schellenberger U. Cysteine 116 participates in intermolecular bonding of the human VEGF(121) homodimer. Arch Biochem Biophys 2002, 404:126-135.